Cargando…
Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection
BACKGROUND: Rifabutin has been found to be effective in multi-resistant patients after various treatment cycles for Helicobacter pylori (HP) infection, but it has not been analysed as a second-line treatment. Therefore, we seek to compare the effectiveness of a treatment regimen including rifabutin...
Autores principales: | Navarro-Jarabo, José M, Fernández, Nuria, Sousa, Francisca L, Cabrera, Encarnación, Castro, Manuel, Ramírez, Luz M, Rivera, Robin, Ubiña, Esther, Vera, Francisco, Méndez, Isabel, Rivas-Ruiz, Francisco, Moreno, José L, Perea-Milla, Emilio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1941741/ https://www.ncbi.nlm.nih.gov/pubmed/17651479 http://dx.doi.org/10.1186/1471-230X-7-31 |
Ejemplares similares
-
Comments regarding use of rifabutin for Helicobacter pylori eradication
por: Graham, David Y.
Publicado: (2021) -
Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial
por: Kalfus, Ira N., et al.
Publicado: (2020) -
Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties
por: Borraccino, Antonia Valeria, et al.
Publicado: (2022) -
Rifabutin for the Treatment of Helicobacter pylori Infection: A Review
por: Gisbert, Javier P.
Publicado: (2020) -
Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen
por: Inokuchi, Kazumi, et al.
Publicado: (2022)